USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS
The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.
1 - 4 . (canceled)
5 . A method of enhancing RUNX3 gene expression or activity comprising:
providing a cell expressing a RUNX3 gene and an miR-532-5p gene; and
contacting the cell with an agent that inhibits miR-532-5p gene or interferes with the interaction between RUNX3 and miR-532-5p transcripts.
6 . The method of claim 5 , wherein the cell is a cancer cell.
7 . The method of claim 6 , wherein the cancer is melanoma, breast cancer, gastric cancer, pancreas cancer, colon cancer, or esophagus cancer.
8 . The method of claim 5 , wherein the agent is an anti-miR-532-5p miRNA.
9 . The method of claim 5 , wherein the agent is a ribonuclease.
10 . A method of treating a cancer comprising administering to a subject suffering from the cancer an effective amount of a compound that inhibits miR-532-5p expression or interferes with the interaction between RUNX3 and mir532-5p transcripts.
11 . The method of claim 10 , wherein the compound is part of a pharmaceutical composition, the pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable carrier.
12 . The method of claim 10 , wherein the compound is an anti-miR-532-5p miRNA.
13 . The method of claim 10 , wherein the compound is a ribonuclease.
14 . The method of claim 10 , wherein the cancer is melanoma, breast cancer, gastric cancer, pancreas cancer, colon cancer, or esophagus cancer.